vTv Therapeutics Inc. (NASDAQ:VTVT) Director Paul G. Savas purchased 15,000 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was bought at an average cost of $4.56 per share, with a total value of $68,400.00. Following the purchase, the director now owns 81,781 shares in the company, valued at $372,921.36. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) traded down $0.14 during trading on Thursday, hitting $4.64. 88,523 shares of the stock were exchanged, compared to its average volume of 31,583. vTv Therapeutics Inc. has a 12 month low of $3.57 and a 12 month high of $8.09.
Several institutional investors have recently made changes to their positions in VTVT. Ameriprise Financial Inc. boosted its stake in shares of vTv Therapeutics by 62.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after purchasing an additional 101,850 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of vTv Therapeutics in the 3rd quarter valued at $481,000. Renaissance Technologies LLC boosted its stake in shares of vTv Therapeutics by 4.8% in the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after purchasing an additional 2,900 shares in the last quarter. State Street Corp boosted its stake in shares of vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of vTv Therapeutics by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,305 shares in the last quarter. 10.42% of the stock is owned by institutional investors.
A number of equities analysts have commented on VTVT shares. Citigroup reissued an “add” rating on shares of vTv Therapeutics in a research note on Wednesday, November 8th. Zacks Investment Research raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research note on Saturday, September 30th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price target on shares of vTv Therapeutics in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. vTv Therapeutics currently has an average rating of “Buy” and an average price target of $14.10.
ILLEGAL ACTIVITY WARNING: “Insider Buying: vTv Therapeutics Inc. (VTVT) Director Purchases 15,000 Shares of Stock” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thelincolnianonline.com/2017/12/07/insider-buying-vtv-therapeutics-inc-vtvt-director-purchases-15000-shares-of-stock.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.